Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 37 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/8/2007 First Published: 5/1/1995


1.		Phase III Randomized Study of Adjuvant Tamoxifen/Fenretinide vs Tamoxifen/Placebo in Postmenopausal Women with Receptor-Positive Breast Cancer (Summary Last Modified 11/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				postmenopausal				NCI				E-EB193 CLB-9443, NCCTG-953052, SWOG-9514, INT-0151, NCT00002646

Last Modified: 9/3/2008 First Published: 10/1/1997


2.		Phase III Randomized, Double Blinded, Placebo Controlled Study of Fenretinide in Patients with Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 (Summary Last Modified 01/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Closed				18 and over				NCI				MDA-ID-92027 NCI-P97-0092, NCT00003075

Last Modified: 3/18/2008 First Published: 11/1/1999


3.		Phase III Randomized Study of Fenretinide in Patients With Resected Superficial Bladder Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				MDA-ID-95236 NCI-G99-1621, NCT00004154, T98-0051, NCI-T98-0051

Last Modified: 4/1/1999 First Published: 11/1/1997


4.		Phase I/II Study of Chemopreventive Agents for the Prevention of Skin Cancer (Summary Last Modified 04/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Prevention				Completed				50-84				NCI				MDA-ID-95184 NCI-P97-0099

Last Modified: 8/1/1999


5.		Phase I/II Pilot Study of Tamoxifen plus the Vitamin A Analogue Fenretinide in Patients with Metastatic Adenocarcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				any age				NCI				ICC-88B3 NCI-T89-0087D, T89-0087

Last Modified: 3/18/2008


6.		Phase IIB Randomized, Double-Blind Chemoprevention Study of Fenretinide vs Placebo in Patients with Resected Transitional Cell Carcinoma of the Bladder at High Risk of Recurrence

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention, Treatment				Completed				adult				NCI				SWOG-9460 NCI-P96-0074

Last Modified: 2/1/1999


7.		Phase II Randomized Double-Blind Study of Fenretinide versus Placebo in Chronic Smokers with Squamous Metaplasia/Dysplasia in the Bronchial Epithelium (Summary Last Modified 02/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Closed				16 and over				NCI				MDA-DM-93018 NCI-P97-0079

Last Modified: 8/1/1998 First Published: 10/1/1997


8.		Phase II Study of Fenretinide (4-Hydroxyphenyl Retinamide; 4-HPR) in Oral Dysplastic Leukoplakia and Oral Dysplasia (Summary Last Modified 08/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Closed				Over 18				NCI				MSGCC-9224 NCI-P97-0098

Last Modified: 1/1/1999 First Published: 11/1/1997


9.		Phase II Study of Fenretinide Prior to Prostatectomy for Prostate Cancer (Summary Last Modified 01/99)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Completed				Over 18				NCI				UAB-9431 NCI-P97-0103

Last Modified: 11/1/1997 First Published: 11/1/1997


10.		Phase II Study of Fenretinide versus Finasteride versus Placebo in Patients with Localized Prostate Cancer (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Closed				40 to 75				NCI				BCM-H2533 NCI-P97-0107

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute